Literature DB >> 21180530

Individualizing HCV Treatment with Peginterferon and Ribavirin: What needs to be Done?

Donald M Jensen1.   

Abstract

Entities:  

Year:  2009        PMID： 21180530      PMCID： PMC3002508          DOI： 10.1177/1756283X08099398

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN： 1756-283X            Impact factor:   4.409


× No keyword cloud information.
  32 in total

1.  Diagnosis, management, and treatment of hepatitis C.

Authors:  Doris B Strader; Teresa Wright; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

2.  Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

Authors:  José M Sánchez-Tapias; Moisés Diago; Pedro Escartín; Jaime Enríquez; Manuel Romero-Gómez; Rafael Bárcena; Javier Crespo; Raúl Andrade; Eva Martínez-Bauer; Ramón Pérez; Milagros Testillano; Ramón Planas; Ricard Solá; Manuel García-Bengoechea; Javier Garcia-Samaniego; Miguel Muñoz-Sánchez; Ricardo Moreno-Otero
Journal:  Gastroenterology       Date:  2006-08       Impact factor: 22.682

3.  Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.

Authors:  J Westin; M Lagging; A P Dhillon; G Norkrans; A I Romero; J-M Pawlotsky; S Zeuzem; S W Schalm; E Verheij-Hart; F Negro; G Missale; A U Neumann; K Hellstrand
Journal:  J Viral Hepat       Date:  2007-01       Impact factor: 3.728

4.  High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.

Authors:  Karin Lindahl; Lars Stahle; Annette Bruchfeld; Robert Schvarcz
Journal:  Hepatology       Date:  2005-02       Impact factor: 17.425

5.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

6.  Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.

Authors:  Thomas Berg; Michael von Wagner; Samer Nasser; Christoph Sarrazin; Tobias Heintges; Tilman Gerlach; Peter Buggisch; Tobias Goeser; Jens Rasenack; Gerd R Pape; Wolfgang E Schmidt; Birgit Kallinowski; Hartwig Klinker; Ulrich Spengler; Peter Martus; Ulrich Alshuth; Stefan Zeuzem
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

7.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Authors:  Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill
Journal:  Ann Intern Med       Date:  2004-03-02       Impact factor: 25.391

8.  Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life.

Authors:  I J Hickman; J R Jonsson; J B Prins; S Ash; D M Purdie; A D Clouston; E E Powell
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

9.  Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.

Authors:  Stefan Zeuzem; Rolf Hultcrantz; Marc Bourliere; Tobias Goeser; Patrick Marcellin; Jose Sanchez-Tapias; Christoph Sarrazin; Joann Harvey; Clifford Brass; Janice Albrecht
Journal:  J Hepatol       Date:  2004-06       Impact factor: 25.083

10.  Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.

Authors:  Brian L Pearlman; Carole Ehleben; Sophia Saifee
Journal:  Hepatology       Date:  2007-12       Impact factor: 17.425
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.